Myomo, Inc. (MYO) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Myomo, Inc. (MYO) stock forecast summary
Our AI ranks Myomo, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Myomo, Inc. is a small-cap company with a market capitalization of $48M. It ranks number 17 by market capitalization among the 27 Orthopedic, Prosthetic & Surgical Appliances & Supplies issuers in our coverage with a current forecast.
For MYO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MYO included.
Follow MYO freeMYO price chart and AI forecast
How MYO ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Myomo, Inc. (MYO) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Orthopedic, Prosthetic & Surgical Appliances & Supplies peers listed below that report each metric.
Valuation & Market
| Metric | MYO | Rank |
|---|---|---|
| Market Cap | $48M | 17/27 |
| P/B Ratio | 8.15x | 6/22 |
| EPS | $-0.35 | – |
| Book Value/Share | $0.15 | – |
| Revenue/Share | $1.09 | – |
| FCF/Share | $-0.18 | – |
Profitability & Margins
| Metric | MYO | Rank |
|---|---|---|
| ROE | -248.9% | 16/19 |
| ROA | -41.0% | 13/19 |
| ROIC | -47.3% | 17/22 |
| Gross Margin | 68.3% | 6/20 |
| Operating Margin | -27.1% | 12/21 |
| Net Margin | -33.5% | 12/17 |
| EBT Margin | -32.5% | 12/21 |
| Tax Rate | -3.1% | – |
Financial Health
| Metric | MYO | Rank |
|---|---|---|
| Current Ratio | 2.31x | 16/25 |
| Quick Ratio | 2.01x | 11/22 |
| D/E Ratio | 5.06x | 3/24 |
| Financial Leverage | 6.06x | 3/24 |
| Interest Coverage | -5.4x | 12/21 |
| Working Capital | $14M | 16/25 |
Cash Flow
| Metric | MYO | Rank |
|---|---|---|
| Operating Cash Flow | -$7M | 18/25 |
| Free Cash Flow | -$7M | 13/16 |
| Capital Spending | -$170K | 5/16 |
| FCF/Sales | -16.8% | 12/16 |
| CapEx/Sales | 0.4% | 13/16 |
Operational Efficiency
| Metric | MYO | Rank |
|---|---|---|
| Asset Turnover | 1.22x | 4/18 |
| Receivables Turnover | 8.8x | 4/17 |
| Inventory Turnover | 0.1x | 22/22 |
| Fixed Assets Turnover | 21.8x | 5/19 |
| Days Sales Outstanding | 42 days | 14/17 |
| Days Inventory | 7769 days | 1/22 |
| Payables Period | 18423 days | 1/19 |
| Cash Conversion Cycle | -10612 days | 15/15 |
Income Statement
| Metric | MYO | Rank |
|---|---|---|
| Total Revenue | $43M | 12/19 |
| Operating Income | -$12M | 16/25 |
| Net Income | -$15M | 12/19 |
| R&D Expense | $6M | 15/22 |
| SG&A Expense | $40M | 13/22 |
| Cost of Goods Sold | $150K | 22/22 |
Dividend & Shareholder Information
| Metric | MYO | Rank |
|---|---|---|
| Shares Outstanding | 40M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $25M | 69.4% of assets |
| Cash & Short-term Investments | $11M | 31.7% of assets |
| Accounts Receivable | $5M | 14.0% of assets |
| Inventory | $3M | 9.0% of assets |
| Total Liabilities | $30M | 83.5% of assets |
| Short-term Debt | $3M | 8.7% of assets |
MYO quarterly financials and insider trading
Myomo, Inc. (MYO) industry peers
Companies classified under the same SEC industry code as Myomo, Inc. (Orthopedic, Prosthetic & Surgical Appliances & Supplies): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| MYO Myomo, Inc. | ▲ | $48M |
| ISRG Intuitive Surgical Inc | ▼ | $150.74B |
| STE Steris Plc | ▼ | $21.71B |
| ZBH Zimmer Biomet Holdings, Inc. | ▼ | $18.12B |
| SNN Smith & Nephew Plc | ▼ | $12.75B |
| ALGN Align Technology Inc | ▶ | $10.46B |
| MSA Msa Safety Inc | ▼ | $6.91B |
| ESTA Establishment Labs Holdings Inc. | ▲ | $1.76B |
| ENOV Enovis Corp | ▶ | $1.13B |
| CDRE Cadre Holdings, Inc. | ▼ | $1.13B |
| AVR Anteris Technologies Global Corp. | ▶ | $590M |
| SMTI Sanara Medtech Inc. | ▼ | $305M |
| INGN Inogen Inc | ▲ | $166M |
| LAKE Lakeland Industries Inc | ▲ | $90M |
| NTRB Nutriband Inc. | ▲ | $76M |
| APT Alpha Pro Tech Ltd | ▲ | $57M |
| COCH Envoy Medical, Inc. | ▼ | $50M |
| MLSS Milestone Scientific Inc. | ▲ | $29M |
| LFWD Lifeward Ltd. | ▲ | $17M |
| CUPR Cuprina Holdings (Cayman) Ltd | ▶ | $13M |
| UEEC United Health Products, Inc. | ▲ | $12M |
| RGNT Regentis Biomaterials Ltd. | ▶ | $11M |
| CLGN Collplant Biotechnologies Ltd | ▶ | $7M |
| LGMK Logicmark, Inc. | ▲ | $1M |
| BBLG Bone Biologics Corp | ▲ | $1M |
| RBOT Vicarious Surgical Inc. | ▼ | $550K |
| FEED Envue Medical, Inc. | ▼ | $450K |
Where MYO sits on the market map
Myomo, Inc. (MYO) stock news
Loading...
Myomo, Inc. (MYO) stock forecast FAQ
What is the Myomo, Inc. (MYO) stock forecast?
Our AI ranks Myomo, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Myomo, Inc. stock predictions?
For MYO, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 35.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Myomo, Inc. forecasts updated?
Myomo, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Myomo, Inc.'s industry peers?
27 issuers in our coverage, MYO included, share the SEC industry code Orthopedic, Prosthetic & Surgical Appliances & Supplies. The largest are: Intuitive Surgical Inc (ISRG), Steris Plc (STE), Zimmer Biomet Holdings, Inc. (ZBH), Smith & Nephew Plc (SNN), Align Technology Inc (ALGN), Msa Safety Inc (MSA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.